Conference on Retroviruses and Opportunistic Infections
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Monografia Arquivo
UNIVERSIDADE ESTADUAL DE CAMPINAS FACULDADE DE EDUCAÇÃO FÍSICA Mauricio dos Santos de Oliveira A Evolução da Ginástica Artística Masculina nos Últimos 20 Anos (1987(1987- ---2007)2007) Campinas 2007 Mauricio dos Santos de Oliveira A Evolução da Ginástica Artística Masculina nos Últimos 20 Anos (1987(1987- ---2007)2007) Trabalho de Conclusão de Curso (Graduação) apresentado à Faculdade de Educação Física da Universidade Estadual de Campinas para obtenção do título de Bacharel em Educação Física. Orientador: Marco Antônio Coelho Bortoleto Campinas 2007 Mauricio dos Santos de Oliveira A Evolução da Ginástica Artística Masculina nos Últimos 20 Anos (1987(1987----2007)2007) Este exemplar corresponde à redação final do Trabalho de Conclusão de Curso (Graduação) defendido por Mauricio dos Santos de Oliveira e aprovado pela Comissão julgadora em: 28/11/2007. Marco Antônio Coelho Bortoleto Orientador Laurita Marconi Schiavon Jorge Sergio Pérez Gallardo Vera Aparecida Madruga Forti Campinas 2007 DEDICATÓRIA Dedico este trabalho aos meus pais, Paulo e Ivani, aos meus irmãos, Paulo Francisco e Verônica, e a todos os meus familiares e amigos que de alguma forma me ajudaram ao longo dessa jornada da graduação. Também gostaria de dedicar este trabalho à todas as pessoas que participaram desse processo e que me auxiliaram nos momentos de dificuldade e que também estiveram ao meu lado nos momentos de alegria. AGRADECIMENTOS Gostaria de expressar aqui a minha eterna gratidão a todas as pessoas que direta ou indiretamente fizeram parte do meu caminho ao longo da graduação. Ao meu orientador e amigo Marquinho pela colaboração, disponibilidade, prontidão e apoio ao longo desse processo. A querida Profª Dr. -
UNIVERSITY of CALIFORNIA RIVERSIDE Investigations Into The
UNIVERSITY OF CALIFORNIA RIVERSIDE Investigations into the Role of TAF1-mediated Phosphorylation in Gene Regulation A Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Cell, Molecular and Developmental Biology by Brian James Gadd December 2012 Dissertation Committee: Dr. Xuan Liu, Chairperson Dr. Frank Sauer Dr. Frances M. Sladek Copyright by Brian James Gadd 2012 The Dissertation of Brian James Gadd is approved Committee Chairperson University of California, Riverside Acknowledgments I am thankful to Dr. Liu for her patience and support over the last eight years. I am deeply indebted to my committee members, Dr. Frank Sauer and Dr. Frances Sladek for the insightful comments on my research and this dissertation. Thanks goes out to CMDB, especially Dr. Bachant, Dr. Springer and Kathy Redd for their support. Thanks to all the members of the Liu lab both past and present. A very special thanks to the members of the Sauer lab, including Silvia, Stephane, David, Matt, Stephen, Ninuo, Toby, Josh, Alice, Alex and Flora. You have made all the years here fly by and made them so enjoyable. From the Sladek lab I want to thank Eugene, John, Linh and Karthi. Special thanks go out to all the friends I’ve made over the years here. Chris, Amber, Stephane and David, thank you so much for feeding me, encouraging me and keeping me sane. Thanks to the brothers for all your encouragement and prayers. To any I haven’t mentioned by name, I promise I haven’t forgotten all you’ve done for me during my graduate years. -
TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase
Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 -Targeted -Targeted 1 , University of of , University SC K.W.B., South Columbia, (U.O., Carolina, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. -
Sr61 Int.Pdf
1 STATE OF OKLAHOMA 2 2nd Session of the 53rd Legislature (2012) 3 SENATE RESOLUTION 61 By: Holt 4 5 6 AS INTRODUCED 7 A Resolution celebrating the Centennial of Jim Thorpe's gold medal-winning performances in the 1912 8 Olympic Games, Oklahoma's rich Olympic tradition, and the growing Oklahoma Olympic movement and its impact 9 on the 2012 Olympic Games in London. 10 11 12 WHEREAS, Jim Thorpe, a native Oklahoman and American Indian, in 13 1912 represented the United States at the Olympic Games in 14 Stockholm, Sweden. Thorpe won gold medals in the pentathlon and 15 decathlon, and was the first American to win a gold medal in the 16 decathlon, in which he set a world record; and 17 WHEREAS, having been voted numerous times as the greatest 18 athlete of the Twentieth Century, Thorpe is widely regarded as 19 America's greatest all-around male athlete and perhaps the greatest 20 athlete who ever lived; and 21 WHEREAS, in celebration of the Centennial of Jim Thorpe's gold 22 medal-winning performances at the 1912 Olympic Games, the Jim Thorpe 23 Museum and Oklahoma Sports Hall of Fame, home of the Jim Thorpe 24 Req. No. 3462 Page 1 1 Award, is featuring a special exhibit on the 1912 Olympics, 2 featuring artifacts from the 1912 games; and 3 WHEREAS, also in celebration of the Centennial of Jim Thorpe's 4 1912 Olympic performance, the Jim Thorpe Native American Games will 5 be held in Oklahoma City from June 10-17; and 6 WHEREAS, in commemoration of this anniversary of Oklahoma's 7 greatest Olympic achievement, the Oklahoma State Senate wishes to 8 honor Jim Thorpe's performances along with the achievements of the 9 15 Olympians in the Oklahoma Sports Hall of Fame, including John 10 Smith, Shannon Miller, Kenny Monday, J.W. -
8Th IAS Conference on HIV Pathogenesis, Treatment &
ONLINE ONLINE OPEN PEER-REVIEWD PEER-REVIEWD ONLINE A PEER-REVIEWD OPEN ACCESS OPEN HIV/AIDS JOURNAL HIV/AIDS JOURNAL CCESS ONLINEONLINE CCESS A OPEN OPEN PEER-REVIEWD ONLINE HIV/AIDS JOURNAL HIV/AIDS HIV/AIDS JOURNAL PEER-REVIEWD PEER-REVIEWD OPEN ACCESSONLINEPEER-REVIEWD A ONLINEPEER-REVIEWD CCESS HIV/AIDS JOURNALPEER-REVIEWD OPEN ACCESS CCESS A OPEN ONLINE ONLINE HIV/AIDS JOURNAL ONLINE PEER-REVIEWDHIV/AIDS JOURNALONLINEONLINE PEER-REVIEWDOPEN ACCESS PEER-REVIEWD ONLINE ONLINE OPEN ACCESSONLINE OPEN HIV/AIDS JOURNAL CCESS OPEN ACCESS HIV/AIDS JOURNAL PEER-REVIEWD PEER-REVIEWD PEER-REVIEWD HIV/AIDS JOURNAL PEER-REVIEWD A HIV/AIDS JOURNAL OPEN ACCESS PEER-REVIEWD PEER-REVIEWD PEER-REVIEWDONLINE HIV/AIDS JOURNAL HIV/AIDS JOURNAL OPEN ACCESS ONLINE ONLINEONLINE HIV/AIDS JOURNAL HIV/AIDS PEER-REVIEWD A PEER-REVIEWD ONLINE ONLINE HIV/AIDS JOURNAL CCESS HIV/AIDS JOURNALOPEN ONLINE PEER-REVIEWDONLINE PEER-REVIEWD HIV/AIDS JOURNAL OPEN PEER-REVIEWDJOURNAL HIV/AIDS HIV/AIDS JOURNAL HIV/AIDS JOURNAL CCESS ONLINE A A ONLINE OPEN ACCESS HIV/AIDS JOURNAL ONLINE HIV/AIDS JOURNAL CCESS PEER-REVIEWD OPEN ACCESS HIV/AIDS JOURNAL OPEN ACCESS ONLINE HIV/AIDS JOURNAL HIV/AIDS ONLINE OPEN OPEN ACCESS HIV/AIDS JOURNAL PEER-REVIEWD OPEN HIV/AIDS JOURNALPEER-REVIEWD PEER-REVIEWD OPEN ACCESS PEER-REVIEWD CCESS A OPEN PEER-REVIEWDONLINE PEER-REVIEWD PEER-REVIEWD HIV/AIDS JOURNALAbstractHIV/AIDS JOURNAL SupplementHIV/AIDS JOURNAL PEER-REVIEWD OPEN ACCESS CCESS PEER-REVIEWD A PEER-REVIEWD A 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention CCESS OPEN ACCESS 19–22 July 2015, Vancouver, Canada OPEN HIV/AIDS JOURNAL Volume 18, Supplement 4 Scan this QR code with your mobile device to view July 2015 the special issue online 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) Journal of the International AIDS Society 2015, 18 (Suppl 4) http://www.jiasociety.org/index.php/jias/article/view/20479 ORAL ABSTRACTS Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice resulted in viral amplification MO Á MONDAY in the mouse. -
Antibody List
產品編號 產品名稱 PA569955 1110059E24Rik Polyclonal Antibody PA569956 1110059E24Rik Polyclonal Antibody PA570131 1190002N15Rik Polyclonal Antibody 01-1234-42 123count eBeads Counting Beads MA512242 14.3.3 Pan Monoclonal Antibody (CG15) LFMA0074 14-3-3 beta Monoclonal Antibody (60C10) LFPA0077 14-3-3 beta Polyclonal Antibody PA137002 14-3-3 beta Polyclonal Antibody PA14647 14-3-3 beta Polyclonal Antibody PA515477 14-3-3 beta Polyclonal Antibody PA517425 14-3-3 beta Polyclonal Antibody PA522264 14-3-3 beta Polyclonal Antibody PA529689 14-3-3 beta Polyclonal Antibody MA134561 14-3-3 beta/epsilon/zeta Monoclonal Antibody (3C8) MA125492 14-3-3 beta/zeta Monoclonal Antibody (22-IID8B) MA125665 14-3-3 beta/zeta Monoclonal Antibody (4E2) 702477 14-3-3 delta/zeta Antibody (1H9L19), ABfinity Rabbit Monoclonal 711507 14-3-3 delta/zeta Antibody (1HCLC), ABfinity Rabbit Oligoclonal 702241 14-3-3 epsilon Antibody (5H10L5), ABfinity Rabbit Monoclonal 711273 14-3-3 epsilon Antibody (5HCLC), ABfinity Rabbit Oligoclonal PA517104 14-3-3 epsilon Polyclonal Antibody PA528937 14-3-3 epsilon Polyclonal Antibody PA529773 14-3-3 epsilon Polyclonal Antibody PA575298 14-3-3 eta (Lys81) Polyclonal Antibody MA524792 14-3-3 eta Monoclonal Antibody PA528113 14-3-3 eta Polyclonal Antibody PA529774 14-3-3 eta Polyclonal Antibody PA546811 14-3-3 eta Polyclonal Antibody MA116588 14-3-3 gamma Monoclonal Antibody (HS23) MA116587 14-3-3 gamma Monoclonal Antibody (KC21) PA529690 14-3-3 gamma Polyclonal Antibody PA578233 14-3-3 gamma Polyclonal Antibody 510700 14-3-3 Pan Polyclonal -
WO2019226953A1.Pdf
) ( 2 (51) International Patent Classification: Street, Brookline, MA 02446 (US). WILSON, Christo¬ C12N 9/22 (2006.01) pher, Gerard; 696 Main Street, Apartment 311, Waltham, MA 0245 1(US). DOMAN, Jordan, Leigh; 25 Avon Street, (21) International Application Number: Somverville, MA 02143 (US). PCT/US20 19/033 848 (74) Agent: HEBERT, Alan, M. et al. ;Wolf, Greenfield, Sacks, (22) International Filing Date: P.C., 600 Atlanitc Avenue, Boston, MA 02210-2206 (US). 23 May 2019 (23.05.2019) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection av ailable) . AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/675,726 23 May 2018 (23.05.2018) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/677,658 29 May 2018 (29.05.2018) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicants: THE BROAD INSTITUTE, INC. [US/US]; MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 415 Main Street, Cambridge, MA 02142 (US). PRESI¬ OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, DENT AND FELLOWS OF HARVARD COLLEGE SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US). -
STOP HIV/AIDS Backgrounder
TREATMENT AS PREVENTION STOP HIV/AIDS STOP HIV/AIDS In 2008, the BC-CfE developed a mathematical On February 4, 2010, then-Minister of Health “TREATMENT AS model and a cost-effectiveness evaluation Kevin Falcon announced a four-year $48 million that suggested that the expansion of HAART pilot aimed to evaluate the impact of the HIV PREVENTION” IN coverage would be highly cost-effective, as it Treatment as Prevention strategy in BC. The would prevent AIDS morbidity and mortality. strategy is a pilot project called STOP HIV/AIDS ACTION However, when the impact of the expansion of (Seek and Treat for Optimal Prevention of HIV HAART coverage on HIV transmission was taken and AIDS). Extending HAART via Treatment as into account, the strategy was found to have the The STOP HIV/AIDS pilot aims to expand access Prevention saves lives, prevents potential of becoming cost-averting, as it would to HIV/AIDS treatment and medication among HIV transmission and reduces health costs virtually eliminate vertical transmission of HIV, hard-to-reach and vulnerable populations in and dramatically reduce HIV transmission by all hile an outright cure or a preventive Vancouver’s Downtown Eastside and Prince other routes. Wvaccine for HIV/AIDS remains elusive, George. These regions had been identified as remarkable advances in HIV treatment have Most recently, HPTN 052—a randomized trial of priority sites for the pilot project because they been achieved over the past two decades. HIV sero-discordant (primarily heterosexual) were disproportionately affected by HIV/AIDS. Most significant among these advances is the couples—provided definitive proof of the The pilot project specifically serves individuals development of highly active antiretroviral efficacy of HIV Treatment as Prevention. -
Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance
University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2013 Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance Alyssa Lea MacMillan University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Virology Commons Recommended Citation MacMillan, Alyssa Lea, "Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance" (2013). Publicly Accessible Penn Dissertations. 894. https://repository.upenn.edu/edissertations/894 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/894 For more information, please contact [email protected]. Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance Abstract APOBEC3 proteins are important for antiretroviral defense in mammals. The activity of these factors has been well characterized in vitro, identifying cytidine deamination as an active source of viral restriction leading to hypermutation of viral DNA synthesized during reverse transcription. These mutations can result in viral lethality via disruption of critical genes, but in some cases is insufficiento t completely obstruct viral replication. This sublethal level of mutagenesis could aid in viral evolution. A cytidine deaminase-independent mechanism of restriction has also been identified, as catalytically inactive proteins are still able to inhibit infection in vitro. Murine retroviruses do not exhibit characteristics of hypermutation by mouse APOBEC3 in vivo. However, human APOBEC3G protein expressed in transgenic mice maintains antiviral restriction and actively deaminates viral genomes. The mechanism by which endogenous APOBEC3 proteins function is unclear. The mouse provides a system amenable to studying the interaction of APOBEC3 and retroviral targets in vivo. -
Supplemental Table S1. Primers for Sybrgreen Quantitative RT-PCR Assays
Supplemental Table S1. Primers for SYBRGreen quantitative RT-PCR assays. Gene Accession Primer Sequence Length Start Stop Tm GC% GAPDH NM_002046.3 GAPDH F TCCTGTTCGACAGTCAGCCGCA 22 39 60 60.43 59.09 GAPDH R GCGCCCAATACGACCAAATCCGT 23 150 128 60.12 56.52 Exon junction 131/132 (reverse primer) on template NM_002046.3 DNAH6 NM_001370.1 DNAH6 F GGGCCTGGTGCTGCTTTGATGA 22 4690 4711 59.66 59.09% DNAH6 R TAGAGAGCTTTGCCGCTTTGGCG 23 4797 4775 60.06 56.52% Exon junction 4790/4791 (reverse primer) on template NM_001370.1 DNAH7 NM_018897.2 DNAH7 F TGCTGCATGAGCGGGCGATTA 21 9973 9993 59.25 57.14% DNAH7 R AGGAAGCCATGTACAAAGGTTGGCA 25 10073 10049 58.85 48.00% Exon junction 9989/9990 (forward primer) on template NM_018897.2 DNAI1 NM_012144.2 DNAI1 F AACAGATGTGCCTGCAGCTGGG 22 673 694 59.67 59.09 DNAI1 R TCTCGATCCCGGACAGGGTTGT 22 822 801 59.07 59.09 Exon junction 814/815 (reverse primer) on template NM_012144.2 RPGRIP1L NM_015272.2 RPGRIP1L F TCCCAAGGTTTCACAAGAAGGCAGT 25 3118 3142 58.5 48.00% RPGRIP1L R TGCCAAGCTTTGTTCTGCAAGCTGA 25 3238 3214 60.06 48.00% Exon junction 3124/3125 (forward primer) on template NM_015272.2 Supplemental Table S2. Transcripts that differentiate IPF/UIP from controls at 5%FDR Fold- p-value Change Transcript Gene p-value p-value p-value (IPF/UIP (IPF/UIP Cluster ID RefSeq Symbol gene_assignment (Age) (Gender) (Smoking) vs. C) vs. C) NM_001178008 // CBS // cystathionine-beta- 8070632 NM_001178008 CBS synthase // 21q22.3 // 875 /// NM_0000 0.456642 0.314761 0.418564 4.83E-36 -2.23 NM_003013 // SFRP2 // secreted frizzled- 8103254 NM_003013 -
Killam Prizes | Prix Killam
Killam Prizes | Prix Killam Year | Winners | University | Discipline Année Gagnants Université 2021 Michel Bouvier Université de Montréal Health Sciences | sciences de la santé Stephen R. Gill York University Social Sciences | sciences sociales Gilbert Laporte HEC Montréal Engineering | génie Arthur Ripstein University of Toronto Humanities | sciences humaines Douglas Stephan University of Toronto Natural Sciences | sciences de la nature 2020 Cecilia Benoit University of Victoria Social Sciences | sciences sociales Sarah Carter University of Alberta Humanities | sciences humaines Alan Evans Montreal Neurological Institute Health Sciences | sciences de la santé Ted Sargent University of Toronto Engineering | génie Barbara Sherwood Lollar University of Toronto Natural Sciences | sciences de la nature 2019 Yoshua Bengio Université de Montréal Natural Sciences | sciences de la nature André Blais Université de Montréal Social Sciences | sciences sociales Keith W. Hipel University of Waterloo Engineering | génie Stephen W. Scherer University of Toronto Health Sciences | sciences de la santé Lynne Viola University of Toronto Humanities | sciences humaines 2018 André Gaudreault Université de Montréal Humanities | sciences humaines Vladimir Hachinski Western University Health Sciences | sciences de la santé Walter Herzog University of Calgary Engineering | génie James Pinfold University of Alberta Natural Sciences | sciences de la nature Janet Werker University of British Columbia Social Sciences | sciences sociales Canada Council for the Arts -
Shannon Miller
SHANNON MILLER Shannon Miller remains one of the most decorated gymnasts in history with 7 Olympic medals. (2 gold, 2 silver, 3 bronze) She is the only female athlete to be inducted into the US Olympic Hall of Fame – Twice! (Individual (2006) and Team (2008). Shannon has won an astounding 59 International and 49 National competition medals. Over half of these have been gold. She is the first US gymnast to win 2 World All-Around Titles. Her tally of five medals (2 silver, 3 bronze) at the 1992 Olympics was the most medals won by a US athlete in any sport. At the ’96 Games, she led the “Magnificent Seven” to the US Women’s first ever Team Gold and for the first time for any American gymnast, she captured Gold on the Balance Beam. After retiring from Olympic competition, Shannon received her undergraduate degrees in marketing and entrepreneurship from the University of Houston and her law degree from Boston College. Shannon remains a part of the gymnastics and Olympic communities as an analyst and commentator. In 2010, Shannon launched her company devoted to helping women make their health a priority. She continues to travel the country as a highly sought-after motivational speaker on topics ranging from The Gold Medal Mindset to cancer and survivorship to the importance of health and fitness. In January of 2011, Shannon was diagnosed with a rare form of ovarian cancer. She had the baseball sized tumor removed successfully and followed up with an aggressive chemotherapy regimen. Shannon has remained open and public about her diagnosis and treatment and continues to empower women to make their health a priority.